Digital PCR Market – Strategy Adopted By Leading Players - Industry Report 2024
According to research report the digital PCR market is projected to reach USD 6.3 billion by 2024 from USD 4.1 billion in 2019, at a CAGR of 8.8% from 2019 to 2024.
The
rising incidences of infectious diseases (such as HIV, tuberculosis,
and malaria) and genetic disorders; continuous technological
advancements in PCR technologies and the commercialization of
lab-on-chip devices and microfluidics-based portable instruments;
increasing investments, funds, and grants for genomic research;
increasing use of biomarker profiling for disease diagnostics; and the
successful completion of the Human Genome Project are expected to
augment the growth of the global Digital PCR Market over the forecast
period. On the other hand, the high instrument costs—especially that of
dPCR—and the technical limitations of PCR are expected to limit market
growth to a certain extent.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174151204
The
major players operating in the Digital PCR Market include Thermo Fisher
Scientific, Inc. (US), Takara Bio, Inc. (Japan), Abbott Laboratories
(US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd.
(Switzerland), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (US),
Fluidigm Corporation (US), bioMérieux S.A. (France), Danaher Corporation
(US), Merck KGaA (Germany), Becton Dickinson and Company (US),
Eppendorf AG (Germany), Promega Corporation (US), and Analytik Jena AG
(Germany).
An analysis of the market developments between 2016
and 2019 revealed that several growth strategies such as product
launches; partnerships and collaborations; acquisitions; and expansions
were adopted by market players to strengthen their product portfolios
and maintain a competitive position in the Digital PCR Market.
Thermo
Fisher Scientific (US) is one of the leading players in the field of
healthcare and life science research. The company possesses a robust
product portfolio in the dPCR and qPCR segment and a strong market
presence globally, with sales and distribution networks in more than 50
countries. It focuses on strengthening its market position in the
Digital PCR Market through product launches, acquisitions, and
partnerships. The company mainly focuses on business strategies that
include launching new products and gaining approvals in order to expand
its product portfolio and offer customers a wide range of dPCR and qPCR
products. Thermo Fisher Scientific also launched several products,
including real-time PCR assay and system. It has received regulatory
approvals for several other clinical assays from respective authorities.
Thermo Fisher Scientific also focuses on acquisitions as a key strategy
to strengthen its market position and expand its product portfolio with
advanced technology products. In 2016, the company acquired Affymetrix,
Inc., (US) which enabled Thermo Fisher to leverage Affymetrix’s
microarray technology for novel product development.
Request Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=174151204
Bio-Rad
Laboratories (US) is one of the leading players in the field of disease
diagnostics & laboratory products. The company has a noteworthy
presence in the dPCR and qPCR industry and a wide geographic presence in
major markets such as the US, Germany, Japan, China, India, and Brazil.
Bio-Rad is involved in the development, manufacturing, and marketing of
more than 5,000 reagents, apparatuses, and laboratory instruments
(including qPCR and dPCR products). The acquisition of RainDance
Technologies in January 2017 enabled Bio-Rad to strengthen its position
in the dPCR market by leveraging RainDance’s droplet microfluid
technology for novel product development and product portfolio
expansion. During 2015–2018, Bio-Rad Laboratories witnessed a steady
rise in the profit margin & annual revenue of its Life Sciences
segment through the commercialization of its dPCR and qPCR instruments,
assays, and software. In the last three years, Bio-Rad has also launched
several dPCR and real-time PCR (qPCR) products to meet the growing
market demand for novel clinical diagnosis products by offering
innovative products to its customers from the research and clinical
field.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Comments
Post a Comment